

Accepted Manuscript

Title: Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation

Author: Maria R. Khouri, Elias J. Jabbour, Alison M. Gulbis, Francesco Turturro, Celina Ledesma, Martin Korbling, Barry I. Samuels, Sairah Ahmed, Amin M. Alousi, Stefan O. Ciurea, David Marin, Krina K. Patel, Uday R. Popat, Carlos E. Bueso-Ramos, Roland L. Bassett Jr., Issa F. Khouri

PII: S1083-8791(17)30445-7
DOI: <http://dx.doi.org/doi: 10.1016/j.bbmt.2017.04.027>
Reference: YBBMT 54659

To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 12-11-2016
Accepted date: 29-4-2017

Please cite this article as: Maria R. Khouri, Elias J. Jabbour, Alison M. Gulbis, Francesco Turturro, Celina Ledesma, Martin Korbling, Barry I. Samuels, Sairah Ahmed, Amin M. Alousi, Stefan O. Ciurea, David Marin, Krina K. Patel, Uday R. Popat, Carlos E. Bueso-Ramos, Roland L. Bassett Jr., Issa F. Khouri, Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation, *Biology of Blood and Marrow Transplantation* (2017), <http://dx.doi.org/doi: 10.1016/j.bbmt.2017.04.027>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after
2 Allogeneic Transplantation

3

4

5 Maria R. Khouri¹, Elias J. Jabbour¹, Alison M. Gulbis², Francesco Turturro³, Celina

6 Ledesma⁴, Martin Korbling⁴, Barry I. Samuels⁵, Sairah Ahmed⁴, Amin M. Alousi⁴, Stefan

7 O. Ciurea⁴, David Marin⁴, Krina K. Patel⁴, Uday R. Popat⁴, Carlos E. Bueso-Ramos⁶,

8 Roland L. Bassett, Jr.⁷, and Issa F. Khouri⁵

9

10 ¹Department of Leukemia, ²Division of Pharmacy, and Departments of ³Lymphoma and

11 Myeloma, ⁴Stem Cell Transplantation and Cellular Therapy,

12 ⁵Diagnostic Radiology, and ⁶Hematopathology, and ⁷Biostatistics, The University of

13 Texas MD Anderson Cancer Center, Houston, TX.

14 Brief report

15 Supported by the NIH/NCI under award number P30CA016672 and by Celgene

16 Corporation.

17 Correspondence: Issa F. Khouri, Department of Stem Cell Transplantation and Cellular

18 Therapy, Unit 423, The University of Texas MD Anderson Cancer Center, 1515

19 Holcombe Blvd., Houston, TX 77030; tel: 713-792-8750; fax: 713-794-4902, e-mail:

20 ikhouri@mdanderson.org.

21

22

23

24

25

Download English Version:

<https://daneshyari.com/en/article/5524129>

Download Persian Version:

<https://daneshyari.com/article/5524129>

[Daneshyari.com](https://daneshyari.com)